{"uri": "eng-9425957", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Immune_thrombocytopenic_purpura", "type": "wiki", "score": 100, "label": {"eng": "Immune thrombocytopenic purpura"}}, {"uri": "http://en.wikipedia.org/wiki/Autoimmune_disease", "type": "wiki", "score": 87, "label": {"eng": "Autoimmune disease"}}, {"uri": "http://en.wikipedia.org/wiki/Platelet", "type": "wiki", "score": 79, "label": {"eng": "Platelet"}}, {"uri": "http://en.wikipedia.org/wiki/Japan", "type": "loc", "score": 78, "label": {"eng": "Japan"}, "location": {"type": "country", "label": {"eng": "Japan"}}}, {"uri": "http://en.wikipedia.org/wiki/Ministry_of_Health,_Labour_and_Welfare", "type": "wiki", "score": 73, "label": {"eng": "Ministry of Health, Labour and Welfare"}}, {"uri": "http://en.wikipedia.org/wiki/Placebo", "type": "wiki", "score": 69, "label": {"eng": "Placebo"}}, {"uri": "http://en.wikipedia.org/wiki/Immunology", "type": "wiki", "score": 62, "label": {"eng": "Immunology"}}, {"uri": "http://en.wikipedia.org/wiki/Doctor_of_Medicine", "type": "wiki", "score": 55, "label": {"eng": "Doctor of Medicine"}}, {"uri": "http://en.wikipedia.org/wiki/Autoantibody", "type": "wiki", "score": 47, "label": {"eng": "Autoantibody"}}, {"uri": "http://en.wikipedia.org/wiki/Intravenous_therapy", "type": "wiki", "score": 47, "label": {"eng": "Intravenous therapy"}}, {"uri": "http://en.wikipedia.org/wiki/Antibody", "type": "wiki", "score": 46, "label": {"eng": "Antibody"}}, {"uri": "http://en.wikipedia.org/wiki/Medication", "type": "wiki", "score": 44, "label": {"eng": "Medication"}}, {"uri": "http://en.wikipedia.org/wiki/Quality_of_life", "type": "wiki", "score": 42, "label": {"eng": "Quality of life"}}, {"uri": "http://en.wikipedia.org/wiki/Thrombocytopenia", "type": "wiki", "score": 40, "label": {"eng": "Thrombocytopenia"}}, {"uri": "http://en.wikipedia.org/wiki/The_Lancet", "type": "wiki", "score": 36, "label": {"eng": "The Lancet"}}, {"uri": "http://en.wikipedia.org/wiki/Biology", "type": "wiki", "score": 36, "label": {"eng": "Biology"}}, {"uri": "http://en.wikipedia.org/wiki/Bleeding", "type": "wiki", "score": 34, "label": {"eng": "Bleeding"}}, {"uri": "http://en.wikipedia.org/wiki/Diagnosis", "type": "wiki", "score": 31, "label": {"eng": "Diagnosis"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 26, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/Thrombopoietin", "type": "wiki", "score": 25, "label": {"eng": "Thrombopoietin"}}, {"uri": "http://en.wikipedia.org/wiki/Agonist", "type": "wiki", "score": 25, "label": {"eng": "Agonist"}}], "eventDate": "2024-03-25", "totalArticleCount": 7, "title": {"eng": "argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary ..."}, "summary": {"eng": "VYVGART \u00ae now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)\n\nRegulatory decision in Japan represents first global approval for VYVGART in ITP\n\nMarch 26, 2024 7:00 AM CET\n\nAmsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVGART (efg"}, "location": null, "categories": [{"uri": "dmoz/Health/Conditions_and_Diseases/Respiratory_Disorders", "label": "dmoz/Health/Conditions and Diseases/Respiratory Disorders", "wgt": 100}, {"uri": "dmoz/Health/Women's_Health/Conditions_and_Diseases", "label": "dmoz/Health/Women's Health/Conditions and Diseases", "wgt": 100}, {"uri": "dmoz/Health/Men's_Health/Conditions_and_Diseases", "label": "dmoz/Health/Men's Health/Conditions and Diseases", "wgt": 100}, {"uri": "news/Health", "label": "news/Health", "wgt": 87}], "articleCounts": {"eng": 7}, "sentiment": 0.3411764705882352, "wgt": 449020800, "relevance": 1}